MA52870A - Peptides ayant une activité inhibitrice sur le récepteur muscarinique m3 - Google Patents

Peptides ayant une activité inhibitrice sur le récepteur muscarinique m3

Info

Publication number
MA52870A
MA52870A MA052870A MA52870A MA52870A MA 52870 A MA52870 A MA 52870A MA 052870 A MA052870 A MA 052870A MA 52870 A MA52870 A MA 52870A MA 52870 A MA52870 A MA 52870A
Authority
MA
Morocco
Prior art keywords
inhibitoral
muscarinic
peptides
receptor
activity
Prior art date
Application number
MA052870A
Other languages
English (en)
Inventor
Cristina Bartella
Giner Isabel Devesa
Ballester Gregorio Fernandez
Montiel Antonio Ferrer
Francesca Mancini
Giorgina Mangano
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of MA52870A publication Critical patent/MA52870A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
MA052870A 2018-06-13 2019-06-11 Peptides ayant une activité inhibitrice sur le récepteur muscarinique m3 MA52870A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18177587 2018-06-13

Publications (1)

Publication Number Publication Date
MA52870A true MA52870A (fr) 2021-04-21

Family

ID=62636028

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052870A MA52870A (fr) 2018-06-13 2019-06-11 Peptides ayant une activité inhibitrice sur le récepteur muscarinique m3

Country Status (6)

Country Link
US (1) US12102705B2 (fr)
EP (1) EP3807294A1 (fr)
JP (2) JP7523358B2 (fr)
EA (1) EA202190018A1 (fr)
MA (1) MA52870A (fr)
WO (1) WO2019238686A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025132812A1 (fr) 2023-12-20 2025-06-26 Antalgenics, S.L. Peptides inhibiteurs de phospholipase c et leurs utilisations

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0971952A2 (fr) * 1997-04-10 2000-01-19 Royal Netherlands Academy of Arts and Sciences Reactifs pour diagnostics et procede correspondant
US6559128B1 (en) * 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
EP1295939A4 (fr) 2000-06-15 2005-02-02 Kyowa Hakko Kogyo Kk Proteine de liaison de facteur de croissance insulinoide
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US20030133912A1 (en) 2001-12-11 2003-07-17 Davidson Beverly L. Receptor-targeted adenoviral vectors
US20050282755A1 (en) 2004-03-18 2005-12-22 Ansata Therapeutics, Inc. Compositions having antimicrobial activity and uses thereof
EP1789453A2 (fr) 2004-05-18 2007-05-30 Genentech, Inc. Principaux variants de la proteine de coque majeure du virus m13 pour affichage c-terminal et bi-terminal d'une proteine heterologue
WO2007048022A2 (fr) * 2005-10-21 2007-04-26 Alexion Pharmaceuticals, Inc. Prroteines de fusion anticorps-polypeptide et methodes de production et d'utilisation
EP2071334A1 (fr) 2007-12-14 2009-06-17 Transmedi SA Compositions et procédés pour la détection de TIABS
JP5818440B2 (ja) 2008-03-12 2015-11-18 オタゴ イノベーション リミテッド バイオマーカー
EP2771349B1 (fr) * 2011-09-16 2020-02-26 Iogenetics, LLC. Procédés bio-informatiques de détermination de liaisons peptidiques
WO2013125221A1 (fr) * 2012-02-21 2013-08-29 静岡県 Ligand d'affinité pour la purification d'anticorps
RU2664473C2 (ru) * 2012-03-16 2018-08-17 Регенерон Фармасьютикалз, Инк. ОТЛИЧНЫЕ ОТ ЧЕЛОВЕКА ЖИВОТНЫЕ, ЭКСПРЕССИРУЮЩИЕ ЧУВСТВИТЕЛЬНЫЕ К pН ПОСЛЕДОВАТЕЛЬНОСТИ ИММУНОГЛОБУЛИНОВ
EP2836193B1 (fr) * 2012-04-13 2018-01-31 Lubrizol Advanced Materials, Inc. Composés inhibant l'exocytosis neuronale (ii)
WO2013172926A1 (fr) 2012-05-14 2013-11-21 Yale University Biomarqueurs immunes et analyses pour prévoir la réponse clinique à une immunothéraphie contre le cancer
WO2014001229A2 (fr) * 2012-06-26 2014-01-03 F. Hoffmann-La Roche Ag Peptides pénétrant les cellules et procédés d'identification de peptides pénétrant les cellules
WO2014200910A2 (fr) 2013-06-10 2014-12-18 Iogenetics, Llc Procédés bio-informatiques de détermination de liaisons peptidiques
WO2016172722A1 (fr) 2015-04-23 2016-10-27 Nantomics, Llc Néo-épitopes de cancer
WO2017120222A1 (fr) 2016-01-04 2017-07-13 Cour Pharmaceuticals Development Company Inc. Particules encapsulant des protéines hybrides contenant des épitopes liés
WO2018223092A1 (fr) * 2017-06-02 2018-12-06 Arizona Board Of Regents On Behalf Of Arizona State University Procédé de création de vaccins anticancéreux personnalisés

Also Published As

Publication number Publication date
US12102705B2 (en) 2024-10-01
WO2019238686A1 (fr) 2019-12-19
JP2021528390A (ja) 2021-10-21
JP7523358B2 (ja) 2024-07-26
US20220142898A1 (en) 2022-05-12
EP3807294A1 (fr) 2021-04-21
EA202190018A1 (ru) 2021-03-17
JP2024045275A (ja) 2024-04-02

Similar Documents

Publication Publication Date Title
KR102763158B9 (ko) 최적화된 항tl1a 항체
EP3752170A4 (fr) Récepteurs d'antigènes chimériques ciblant le micro-environnement
IL281428A (en) Chimeric antigen receptor
EP3518708A4 (fr) Structure d'assise souple
EP3449388A4 (fr) Prédicteur d'ensemble
EP3692072A4 (fr) Anticorps anti-hla-dq2.5
EP3763567A4 (fr) Siège
EP3755296A4 (fr) Support d'assise
EP3782777A4 (fr) Dispositif de support du type bras
EP3936006A4 (fr) Siège
IL279780A (en) Compositions and methods for agonizing the cb2 receptor
EP3823857A4 (fr) Siège de voiture portable
DK3840144T3 (da) Skifteanordningen
EP3811824A4 (fr) Siège
EP3761922C0 (fr) Support d'épaule orthétique
EP3693388A4 (fr) Anticorps monoclonal pour il-5r
MA52870A (fr) Peptides ayant une activité inhibitrice sur le récepteur muscarinique m3
EP4008404A4 (fr) Récepteur d'antigène
EP3883968A4 (fr) Région fc modifiée
MA52869A (fr) Peptides ayant une activité inhibitrice sur l'exocytose neuronale
EP4028507A4 (fr) Assembloïdes neuromodulateurs fonctionnels
EP3892371A4 (fr) Structure fonctionnelle
EP4051056C0 (fr) Siège mobile
UA39020S (uk) Пенал для ванної кімнати
IT201900023247A1 (it) Dispositivo di seduta